Marker Therapeutics (MRKR) Leases (2019 - 2023)
Marker Therapeutics (MRKR) has disclosed Leases for 5 consecutive years, with $5.3 million as the latest value for Q1 2023.
- Quarterly Leases fell 44.52% to $5.3 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Mar 2023, down 44.52% year-over-year, with the annual reading at $5.5 million for FY2022, 44.26% down from the prior year.
- Leases for Q1 2023 was $5.3 million at Marker Therapeutics, down from $5.5 million in the prior quarter.
- The five-year high for Leases was $11.1 million in Q3 2020, with the low at $300000.0 in Q2 2020.
- Average Leases over 5 years is $5.9 million, with a median of $5.6 million recorded in 2022.
- The sharpest move saw Leases tumbled 45.2% in 2020, then soared 3333.33% in 2021.
- Over 5 years, Leases stood at $455174.0 in 2019, then skyrocketed by 2282.41% to $10.8 million in 2020, then dropped by 9.35% to $9.8 million in 2021, then plummeted by 44.26% to $5.5 million in 2022, then dropped by 2.8% to $5.3 million in 2023.
- According to Business Quant data, Leases over the past three periods came in at $5.3 million, $5.5 million, and $5.6 million for Q1 2023, Q4 2022, and Q3 2022 respectively.